Trials / Not Yet Recruiting
Not Yet RecruitingNCT07289750
The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD
The Effect of Alogliptin Combined With Pioglitazone and Metformin Hydrochloride Tablets on Glucose and Lipid Metabolism and Islet Function in Patients With Type 2 Diabetes Mellitus Complicated With Metabolic Dysfunction-associated Fatty Liver Disease
- Status
- Not Yet Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To compare the efficacy and safety of the combination of alogliptin and actoplus met with that of actoplus met alone in improving the glucose and lipid metabolism and pancreatic function in T2DM patients complicated with MAFLD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | alogliptin and actoplus met | combination of alogliptin and actoplus met |
| DRUG | actoplus met | actoplus met |
Timeline
- Start date
- 2026-05-01
- Primary completion
- 2027-08-31
- Completion
- 2027-08-31
- First posted
- 2025-12-17
- Last updated
- 2026-03-24
Source: ClinicalTrials.gov record NCT07289750. Inclusion in this directory is not an endorsement.